Securities & Exchange Commission v. Bankosky

716 F.3d 45, 91 A.L.R. Fed. 2d 745, 2013 WL 1955809, 2013 U.S. App. LEXIS 9669
CourtCourt of Appeals for the Second Circuit
DecidedMay 14, 2013
DocketDocket 12-2943-cv
StatusPublished
Cited by28 cases

This text of 716 F.3d 45 (Securities & Exchange Commission v. Bankosky) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Securities & Exchange Commission v. Bankosky, 716 F.3d 45, 91 A.L.R. Fed. 2d 745, 2013 WL 1955809, 2013 U.S. App. LEXIS 9669 (2d Cir. 2013).

Opinion

PER CURIAM:

In this case, the Securities and Exchange Commission (the “SEC”) accused defendant-appellant Brent C. Bankosky of engaging in insider trading, in violation of sections 10(b) and 14(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), 15 U.S.C. §§ 788(b), 78n(e), and SEC Rules 10b-5 and 14e-3. After the entry of a consent judgment, in which Ban-kosky neither admitted nor denied the allegations in the complaint, the SEC moved for an officer and director bar pursuant to section 21(d)(2) of the Exchange Act, 15 U.S.C. § 78u(d)(2). Relying on the factors in SEC v. Patel 61 F.3d 137 (2d Cir.1995), the district court found Bankosky “unfit” to serve as an officer or director of a public company and barred him from acting as one for ten years. Bankosky appeals from the post-judgment opinion and order, arguing that the district court erred in balancing the Patel factors. We affirm.

BACKGROUND

The parties stipulated in the consent judgment that the following factual allegations in the complaint are to be deemed as true solely for the purpose of deciding the SEC’s motion for an officer and director bar:

From January 2008 until his resignation in May 2011, Bankosky worked for the pharmaceutical company Takeda Pharmaceuticals International, Inc. (“Takeda”), first as a director of Global Licensing and Business Development and then as a senior director. In these positions, Bankosky had access to, and did obtain, material non-public information regarding Takeda’s discussions with outside companies about strategic alliances, mergers, and product acquisitions. Despite a company policy prohibiting trading on such inside information, from 2008 to 2011 Bankosky bought call options in the shares of four companies in advance of anticipated deal announcements between these companies and Take-da. After deals with two of the companies were publicly announced, Bankosky sold the options in those companies and realized profits of $63,000. His option investments in the other two companies netted no gain.

On February 9, 2012, the SEC filed this action below. The consent judgment was entered March 15, 2012, imposing a permanent injunction against further viola *47 tions, ordering disgorgement of $63,000 plus pre-judgment interest, and imposing a civil penalty of $63,000.

On March 30, 2012, the SEC moved for the district court to bar Bankosky permanently from serving as an officer or director of any company whose shares are registered under the Exchange Act. In support of its motion, the SEC attached excerpts of Bankosky’s sworn testimony before the SEC and emails that Bankosky sent while working at Takeda. In the testimony, Bankosky denied having any knowledge about Takeda’s entry into a strategic global alliance with Cell Genesys before the public announcement. But emails referenced in the complaint and attached as exhibits to the SEC’s motion demonstrate that Bankosky was aware of the confidential negotiations with Cell Gen-esys and even worked on the project before it went public.

In a May 21, 2012 opinion and order, the district court evaluated Bankosky’,s fitness to serve as an officer or director, applying the six factors set out in SEC v. Patel, 61 F.3d 137 (2d Cir.1995), See, SEC v. Bankosky, No. 12 Civ. 1012, 2012 WL 1849000, at *1-3 (S.D.N.Y. May 21, 2012). In Ban-kosky’s favor, the district court noted that his conduct, though “undeniably serious and not isolated,” was not the sort typically considered egregious and the fact that he was not a repeat offender was “particularly relevant.” Id. at *2. On the other hand, the court made the following findings against him: Bankosky, though not an officer or director, was “acting in a corporate or fiduciary capacity ... where he and his colleagues were involved in the due diligence and negotiations for deals with other pharmaceutical companies”; he knowingly engaged in insider trading; his misleading SEC testimony was particularly troubling; he had a personal economic stake in the trades; and, given his continued effort to contest the wrongfulness of his actions, there were no “assurances against future misconduct.” Id. at *2-3 (quotation omitted). Balancing all of these factors, the court prohibited Bankosky from acting as an officer or director of any public company for ten years. Id. at *4.

This appeal followed.

DISCUSSION

A. Applicable Law

The district court has “substantial discretion in deciding whether to impose a bar to employment in a public company.” Patel, 61 F.3d at 141. Accordingly, we review the district court’s issuance of an officer and director bar for abuse of discretion. See SEC v. Posner, 16 F.3d 520, 521 (2d Cir.1994). Under this standard, “we will reverse only if we have ‘a definite and firm conviction that the court below committed a clear error of judgment in the conclusion that it reached upon a weighing of the relevant factors.’ ” Anderson v. Beland (In re Am. Express Fin. Advisors Sec. Litig.), 672 F.3d 113, 129 (2d Cir.2011) (quoting Silivanch v. Celebrity Cruises, Inc., 333 F.3d 355, 362 (2d Cir.2003)).

Section 21(d)(2) of the Exchange Act provides that:

the court may prohibit, conditionally or unconditionally, and permanently or for such period of time as it shall determine, any person who violated section [10(b) ] of this title or the rules or regulations thereunder from acting as an officer or director of any issuer that has a class of securities registered pursuant to section [12] of this title or that is required to file reports pursuant to section [15(d) ] of this title if the person’s conduct demonstrates unfitness to serve as an officer or director of any such issuer.

*48 15 U.S.C. § 78u(d)(2). In SEC v. Patel, we identified six non-exclusive factors that were “useful in making the unfitness assessment”:

(1) the egregiousness of the underlying securities law violation; (2) the defendant’s repeat offender status; (3) the defendant’s role or position when he engaged in the fraud; (4) the defendant’s degree of scienter; (5) the defendant’s economic stake in the violation; and (6) the likelihood that misconduct will recur.

Patel, 61 F.3d at 141 (quotation omitted) (citing Jayne W. Barnard,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
716 F.3d 45, 91 A.L.R. Fed. 2d 745, 2013 WL 1955809, 2013 U.S. App. LEXIS 9669, Counsel Stack Legal Research, https://law.counselstack.com/opinion/securities-exchange-commission-v-bankosky-ca2-2013.